This study is testing if **dasiglucagon** (a medicine) is safe and helps treat hypoglycemia (low blood sugar) in children under 6 years old with **T1D** (Type 1 Diabetes). The study will look at how the medicine works in the body, called pharmacokinetics (how the body absorbs and breaks down the medicine) and pharmacodynamics (how the medicine affects the body).

Each child will get one injection of dasiglucagon under the skin near the buttocks. There will be 3 visits over 84 days: a screening visit, a dosing visit where the child gets the injection, and a safety check-up visit.

• Study lasts up to 84 days with 3 visits.
• Participants receive one injection of the medicine.
• Safety and how the medicine works are closely monitored.

Children must weigh over 8 kg, be under 6 years old, and have T1D. Children with allergies to the medicine or those with certain medical conditions cannot participate. The study aims to ensure the medicine safely raises blood sugar levels in young children. Safety checks are done thoroughly for each child before and after the injection.